🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are escalating around the world, with figures suggesting more than 82 million infections annually. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to findings detailed in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The study enrolled over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have expressed optimism. Having a single-dose, oral treatment like this is seen as a "revolutionary step" for gonorrhoea control. This is deemed essential to reduce the burden of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.